Endometrial 18F-FDG Uptake in Premenopausal Patients Without Gynecologic Malignancy
| Characteristic | No. of patients | SUV ± SD | ||
|---|---|---|---|---|
| Mean | Range | |||
| Cyclic phase | ||||
| Menstrual flow phase | 23 | 5 ± 3.2 | 2.3–16.6 | |
| Proliferative phase | 21 | 2.6 ± 1.1 | 1.1–5.7 | |
| Ovulatory phase | 26 | 3.7 ± 0.9 | 2–5.4 | |
| Secretory phase | 15 | 2.5 ± 1.1 | 1.3–5.6 | |
| Cyclic abnormalities | ||||
| Oligomenorrhea | 19 | 3.4 ± 1.4 | 1.4–6.2 | |
| Amenorrhea | 8 | 1.9 ± 1.2 | 0.9–4.9 | |
SUV was calculated as the ratio of activity per cubic centimeter of tissue to activity in the injected dose per kilogram of patient body weight.